Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Published by: Global Markets Direct

Published: May. 29, 2008 - 300 Pages

Table of Contents

1 Table Of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Definitions

2.2.1 Drug delivery devices

3 Healthcare Sector Review

3.1 Healthcare Sector Review

3.2 Healthcare Expenditure

3.3 Healthcare Infrastructure

3.4 Healthcare Policy

4 Drug Delivery Devices in Japan

4.1 Drug Delivery Devices Overall Revenues (2000-2012)

4.2 Drug Delivery Devices Overall Volume (2000-2012)

4.3 Drug Delivery Devices Company Shares (2005-2006)

5 Inhalation Systems in Japan

5.1 Inhalation Systems Overall Revenues (2000-2012)

5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)

5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)

5.2 Inhalation Systems Overall Volume (2000-2012)

5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)

5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)

5.3 Inhalation Systems Average Price (2000-2012)

5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)

5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)

5.4 Inhalation Systems Distribution Share (2005-2006)

5.5 Inhalation Systems Company Share (2005-2006)

6 Infusion Systems in Japan

6.1 Infusion Systems Overall Revenues (2000-2012)

6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)

6.1.2 Syringe Pumps Overall Revenue (2000-2012)

6.1.3 Infusion Pumps Overall Revenues (2000-2012)

6.2 Infusion Systems Overall Volume (2000-2012)

6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)

6.2.2 Syringe Pumps Overall Volume (2000-2012)

6.2.3 Infusion Pumps Overall Volume (2000-2012)

6.3 Infusion Systems Average Price (2000-2012)

6.3.1 Infusion Pumps Average Price (2000-2012)

6.3.2 Syringe Pumps Average Price (2000-2012)

6.3.3 Infusion Disposable Sets Average Price (2000-2012)

6.4 Infusion Systems Distribution Share (2005-2006)

6.5 Infusion Systems Company Share (2005-2006)

7 Needle Free Injections in Japan

7.1 Needle Free Injections Overall Revenue (2000-2012)

7.2 Needle Free Injections Overall Volume (2000-2012)

7.3 Needle Free Injections Average Price (2000-2012)

7.4 Needle Free Injections Distribution Share (2005-2006)

7.5 Needle Free Injections Company Share (2005-2006)

8 AstraZeneca PLC Company Profile

8.1 Company Overview

8.2 Business Overview

8.2.1 Products

8.2.2 History

8.3 Locations And Subsidiaries

8.4 Financial Deals Landscape

8.4.1 AstraZeneca Completes $6,900 Million Private Placement

8.4.2 AstraZeneca Acquires MedImmune

8.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics

8.4.4 AstraZeneca Acquires Arrow Therapeutics

8.4.5 AstraZeneca Signs An Agreement With Palatin Technologies

8.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb

8.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals

8.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical

8.4.9 Schering Signs An Agreement With AstraZeneca

8.4.10 AstraZeneca Signs An Agreement With Pozen

8.4.11 AstraZeneca Signs An Agreement With Abbott

8.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience

8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals

8.4.14 AstraZeneca Acquires A Stake In Protherics

8.4.15 AstraZeneca Signs An Agreement With Targacept

8.4.16 AstraZeneca Signs An Agreement With AtheroGenics

8.4.17 AstraZeneca UK Signs An Agreement With Protherics

8.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft

8.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics

8.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals

8.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta

8.4.22 AstraZeneca Completes Private Placement Of $750 million

8.4.23 AstraZeneca Prices EUR750 Million Private Placement

8.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement

8.5 Recent Developments

8.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case

8.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director

8.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs

8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO

8.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member

8.5.6 Jun 06, 2007: AstraZeneca CFO Resigns

8.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site

8.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development

8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston

9 3M Company Profile

9.1 Company Overview

9.2 Business Overview

9.2.1 Consumer and Office

9.2.2 Display and Graphics

9.2.3 Electro and Communications

9.2.4 Health Care

9.2.5 Industrial and Transportation

9.2.6 Safety, Security and Protection Services

9.2.7 Products

9.3 Value Chain Analysis

9.3.1 Manufacturing

9.3.2 Product Development

9.3.3 Sales and Marketing

9.4 SWOT Analysis

9.4.1 3M Company Strengths

3M Company Weaknesses

3M Company Opportunities

3M Company Threats

9.5 Revenue Analysis

9.5.1 Revenue by Segment

9.5.2 Revenue by Geography

9.6 Financial and Operational Review

9.6.1 Financial Statements

9.6.2 Financial Ratios

9.7 Locations And Subsidiaries

9.8 Financial Deals Landscape

9.8.1 3M Canada Acquires Les Entreprises Solumed

9.8.2 3M Acquires Bondo

9.8.3 3M Acquires Lingualcare

9.8.4 3M Acquires Abzil Industria E Comercio

9.8.5 3M Acquires Neo Plast

9.8.6 3M Acquires Assets Of DMS Chile

9.8.7 3M Acquires Business Of Innovative Paper Technologies

9.8.8 3M Acquires Powell

9.8.9 Gen-Probe Signs An Agreement With 3M Company

9.8.10 3M Acquires Acolyte Biomedica

9.8.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp.

9.8.12 3M Sells Its Pharmaceutical Business To Meda AB

9.8.13 3M Acquires SoftMed Systems

9.8.14 3M Sells its Pharmaceuticals Business to Graceway

9.8.15 Gen-Probe Signs An Agreement With 3M

9.8.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital

9.8.17 3M Acquires Biotrace International

9.8.18 Ekahau Secures $16 Million In Additional Funding

9.8.19 3M Acquires Brontes Technologies

9.8.20 3M acquires Nylonge Corp

9.8.21 3M Signs An Agreement With ClozeX Medical

9.8.22 3M Acquires OMNII Oral Pharmaceuticals

9.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway

9.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB

9.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital

9.8.26 3M Acquires Accuspray Application Technologies Inc.

9.8.27 3M to acquire Rochford Thompson Equipment

9.8.28 3M To Acquire Aearo Technologies From Permira

9.8.29 Permira To Sell Aearo Technologies To 3M

9.9 Recent Developments

9.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses

9.9.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State

9.9.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia

9.9.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia

9.9.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year

9.9.6 Nov 12, 2007: 3M Declares Quarterly Dividend

9.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery

9.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend

9.9.9 May 08, 2007: 3M Declares Quarterly Dividend

9.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests

10 Baxter International Company Profile

10.1 Company Overview

10.2 Business Overview

10.2.1 BioScience

10.2.2 Medication Delivery

10.2.3 Renal

10.2.4 Products

10.2.5 History

10.3 Value Chain Analysis

10.3.1 Manufacturing

10.3.2 Product Development

10.3.3 Sales and Marketing

10.4 SWOT Analysis

10.4.1 Baxter International Inc. Strengths

10.4.2 Baxter International Inc. Weaknesses

10.4.3 Baxter International Inc. Opportunities

10.4.4 Baxter International Inc. Threats

10.5 Revenue Analysis

10.5.1 Revenue by Segment

10.5.2 Revenue by Geography

10.6 Financial and Operational Review

10.6.1 Financial Statements

10.6.2 Financial Ratios

10.7 Locations And Subsidiaries

10.8 Financial Deals Landscape

10.8.1 Baiyunshan And Baxter Form A Joint Venture In China

10.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration

10.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital

10.8.4 B. Braun Acquires Renal Therapy Business Of Baxter

10.8.5 Innovata signs a license agreement with Baxter International

10.8.6 Kuros Biosurgery Signs An Agreement With Baxter International

10.8.7 Gambro Signs An Agreement With Baxter

10.8.8 Baxter Healthcare And Gambro Enter Into An Agreement

10.8.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System

10.8.10 Baxter International And Kaketsuken Enter Into Agreement

10.8.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful

10.9 Recent Developments

10.9.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007

10.9.2 Dec 18, 2007: Baxter Elects CFO

10.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend

10.9.4 Aug 01, 2007: Baxter Elects New Board Director

10.9.5 Jul 31, 2007: Baxter Announces Quarterly Dividend

10.9.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization

10.9.7 Feb 13, 2007: Baxter Announces Quarterly Dividend

10.9.8 Nov 28, 2006: Baxter Announces Annual Dividend

10.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America

10.10 Baxter International Inc. Pipeline Products

10.10.1 Next-Generation Home Hemodialysis Machine

11 GlaxoSmithKline plc Company Profile

11.1 Company Overview

11.2 Business Overview

11.2.1 Products

11.2.2 History

11.3 Locations And Subsidiaries

11.4 Financial Deals Landscape

11.4.1 GlaxoSmithKline Acquires CNS

11.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline

11.4.3 CNS To Merge With GlaxoSmithKline

11.5 Recent Developments

11.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007

11.5.2 Feb 07, 2008: Full-year results announcement 2007

11.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance

11.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics

11.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes

12 Novartis AG Company Profile

12.1 Company Overview

12.2 Business Overview

12.2.1 Major Products and Services

12.3 Locations And Subsidiaries

12.4 Financial Deals Landscape

12.4.1 Bayer Schering Pharma Acquires U.S. Biologics Manufacturing Facility From Novartis

12.4.2 Novartis To Acquire Majority Stake In Alcon From Nestle

12.4.3 Novartis to sell Medical Nutrition business unit to Nestlé

12.4.4 Nestlé to Acquire Novartis Medical Nutrition

12.4.5 Novartis to sell its division Gerber Products Company to Nestle

13 Regulation System

13.1 Medical Equipment Approval Process

13.1.1 Market Authorization Holder (MAH)

13.1.2 Classification and Pre-Market Approval of Medical Devices

13.1.3 Third Party Certification for Controlled Medical Devices

13.1.4 PMDA Approval for Highly Controlled Medical Devices

13.1.5 Registration Time

13.1.6 Registration Fee

13.1.7 Post Marketing Surveillance

13.1.8 Labeling and Packaging

14 Pricing and Reimbursement

14.1 Market Pricing

14.2 Reimbursement Policies

14.3 Reimbursement Classes

14.3.1 Class A

14.3.2 Class B

14.3.3 Class C

14.3.4 Class F

14.4 Request for Reimbursement

14.5 Reduction in Reimbursement for Medical Devices and Drugs

15 Distribution Structure

16 APPENDIX

16.1 Global Markets Direct Research Methodology

16.2 Coverage

16.3 Secondary Research

16.4 Primary Research

16.5 Models

16.6 Forecasts

16.7 Expert Panels

16.8 Currency Conversion

16.9 Contact Us

16.10 Disclaimer

1.1 List of Tables

Table 1: Healthcare Expenditure in Japan, 2000 - 2005

Table 2: Number of Healthcare Institutions in Japan, 1995 - 2004

Table 3: Number of Hospital Beds in Japan, 1995 - 2004

Table 4: Number of Medical Personnel in Japan, 1995 - 2004

Table 5: Number of Medical Care Institutions and Beds in Japan, 2000 - 2004

Table 6: Drug Delivery Devices, Japan, Overall Revenues ($ mn), 2000-2012

Table 7: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 8: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 9: Drug Delivery Devices, Japan, Category Revenues ($ mn), 2000-2012

Table 10: Drug Delivery Devices, Japan, Category Revenues ($ mn), Historic, 2000-2007

Table 11: Drug Delivery Devices, Japan, Category Revenues ($ mn), Forecast, 2007-2012

Table 12: Drug Delivery Devices, Japan, Category Volume (Units), 2000-2012

Table 13: Drug Delivery Devices, Japan, Category Volume (Units), Historic, 2000-2007

Table 14: Drug Delivery Devices, Japan, Category Volume (Units), Forecast, 2007-2012

Table 15: Drug Delivery Devices, Japan, Company Share by Revenue ($ mn), 2005-2006

Table 16: Inhalation Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 17: Inhalation Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 18: Inhalation Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007

Table 19: Inhalation Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 20: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 21: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 22: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 23: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 24: Inhalation Systems, Japan, Overall Volume (Units), Historic, 2000-2007

Table 25: Inhalation Systems, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 26: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007

Table 27: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 28: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007

Table 29: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 30: Metered Dose Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007

Table 31: Metered Dose Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012

Table 32: Dry Powder Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007

Table 33: Dry Powder Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012

Table 34: Inhalation Systems, Japan, Distribution Share by Revenue ($ mn), 2005-2006

Table 35: Inhalation Systems, Japan, Company Share by Revenue ($ mn), 2005-2006

Table 36: Infusion Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 37: Infusion Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 38: Infusion Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007

Table 39: Infusion Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 40: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 41: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 42: Syringe Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 43: Syringe Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 44: Infusion Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 45: Infusion Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 46: Infusion Systems, Japan, Overall Volume (Units), Historic, 2000-2007

Table 47: Infusion Systems, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 48: Infusion Disposable Sets, Japan, Overall Volume (Units), Historic, 2000-2007

Table 49: Infusion Disposable Sets, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 50: Syringe Pumps, Japan, Overall Volume (Units), Historic, 2000-2007

Table 51: Syringe Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 52: Infusion Pumps, Japan, Overall Volume (Units), Historic, 2000-2007

Table 53: Infusion Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 54: Infusion Pumps, Japan, Average Price ($), Historic, 2000-2007

Table 55: Infusion Pumps, Japan, Average Price ($), Forecast, 2007-2012

Table 56: Syringe Pumps, Japan, Average Price ($), Historic, 2000-2007

Table 57: Syringe Pumps, Japan, Average Price ($), Forecast, 2007-2012

Table 58: Infusion Disposable Sets, Japan, Average Price ($), Historic, 2000-2007

Table 59: Infusion Disposable Sets, Japan, Average Price ($), Forecast, 2007-2012

Table 60: Infusion Systems, Japan, Distribution Share by Revenue ($ mn), 2005-2006

Table 61: Infusion Systems, Japan, Company Share by Revenue ($ mn), 2005-2006

Table 62: Needle Free Injections, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Table 63: Needle Free Injections, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Table 64: Needle Free Injections, Japan, Overall Volume (Units), Historic, 2000-2007

Table 65: Needle Free Injections, Japan, Overall Volume (Units), Forecast, 2007-2012

Table 66: Needle Free Injections, Japan, Average Price ($), Historic, 2000-2007

Table 67: Needle Free Injections, Japan, Average Price ($), Forecast, 2007-2012

Table 68: Needle Free Injections, Japan, Distribution Share by Revenue ($ mn), 2005-2006

Table 69: Needle Free Injections, Japan, Company Share by Revenue ($ mn), 2005-2006

Table 70: AstraZeneca PLC, Subsidiaries

Table 71: 3M Company, SWOT Analysis, 2006

Table 72: 3M Company, Revenue by Segment, USD Million, 2003-2007

Table 73: 3M Company, Revenue by Geography, USD Million, 2003-2007

Table 74: 3M Company, Financial Statements, USD Million, 2003-2007

Table 75: 3M Company, Financial Ratios, USD Million, 2003-2007

Table 76: 3M Company, Subsidiaries

Table 77: Baxter International Inc., SWOT Analysis, 2006

Table 78: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007

Table 79: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007

Table 80: Baxter International Inc., Financial Statements, USD Million, 2003-2007

Table 81: Baxter International Inc., Financial Ratios, USD Million, 2003-2007

Table 82: Baxter International Inc., Other Locations

Table 83: Baxter International Inc., Subsidiaries

Table 84: GlaxoSmithKline plc, Subsidiaries

Table 84: GlaxoSmithKline plc, Subsidiaries(Contd..)

Table 85: Novartis Medical Nutrition, Other Locations

Table 85: Novartis Medical Nutrition, Other Locations(Contd..)

Table 86: Registration Processing Time for Medical Devices in Japan, 2007

Table 87: Product Registration Fee for Medical Devices in Japan, 2007

Table 88: Currency Conversion from USD to Local Currency at 2007 Constant Rate

1.2 List of Figures

Figure 1: Healthcare Expenditure in Japan, 2000 - 2005

Figure 2: Government and Private Healthcare Expenditure in Japan, 2005

Figure 3: Drug Delivery Devices, Japan, Overall Revenues ($ mn), 2000-2012

Figure 4: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 5: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 6: Drug Delivery Devices, Japan, Category Revenues ($ mn), 2000-2012

Figure 7: Drug Delivery Devices, Japan, Category Revenues ($ mn), Historic, 2000-2007

Figure 8: Drug Delivery Devices, Japan, Category Revenues ($ mn), Forecast, 2007-2012

Figure 9: Drug Delivery Devices, Japan, Category Volume (Units), 2000-2012

Figure 10: Drug Delivery Devices, Japan, Category Volume (Units), Historic, 2000-2007

Figure 11: Drug Delivery Devices, Japan, Category Volume (Units), Forecast, 2007-2012

Figure 12: Drug Delivery Devices, Japan, Company Share (%), 2006

Figure 13: Inhalation Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 14: Inhalation Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 15: Inhalation Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 16: Inhalation Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 17: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 18: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 19: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 20: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 21: Inhalation Systems, Japan, Overall Volume (Units), Historic, 2000-2007

Figure 22: Inhalation Systems, Japan, Overall Volume (Units), Forecast, 2007-2012

Figure 23: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007

Figure 24: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012

Figure 25: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007

Figure 26: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012

Figure 27: Metered Dose Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007

Figure 28: Metered Dose Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012

Figure 29: Dry Powder Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007

Figure 30: Dry Powder Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012

Figure 31: Inhalation Systems, Japan, Distribution Share (%), 2006

Figure 32: Inhalation Systems, Japan, Company Share (%), 2006

Figure 33: Infusion Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 34: Infusion Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 35: Infusion Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 36: Infusion Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 37: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 38: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 39: Syringe Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 40: Syringe Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 41: Infusion Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 42: Infusion Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 43: Infusion Disposable Sets, Japan, Overall Volume (Units), Historic, 2000-2007

Figure 44: Infusion Disposable Sets, Japan, Overall Volume (Units), Forecast, 2007-2012

Figure 45: Syringe Pumps, Japan, Overall Volume (Units), Historic, 2000-2007

Figure 46: Syringe Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012

Figure 47: Infusion Pumps, Japan, Overall Volume (Units), Historic, 2000-2007

Figure 48: Infusion Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012

Figure 49: Infusion Pumps, Japan, Average Price ($), Historic, 2000-2007

Figure 50: Infusion Pumps, Japan, Average Price ($), Forecast, 2007-2012

Figure 51: Syringe Pumps, Japan, Average Price ($), Historic, 2000-2007

Figure 52: Syringe Pumps, Japan, Average Price ($), Forecast, 2007-2012

Figure 53: Infusion Disposable Sets, Japan, Average Price ($), Historic, 2000-2007

Figure 54: Infusion Disposable Sets, Japan, Average Price ($), Forecast, 2007-2012

Figure 55: Infusion Systems, Japan, Distribution Share (%), 2006

Figure 56: Infusion Systems, Japan, Company Share (%), 2006

Figure 57: Needle Free Injections, Japan, Overall Revenues ($ mn), Historic, 2000-2007

Figure 58: Needle Free Injections, Japan, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 59: Needle Free Injections, Japan, Overall Volume (Units), Historic, 2000-2007

Figure 60: Needle Free Injections, Japan, Overall Volume (Units), Forecast, 2007-2012

Figure 61: Needle Free Injections, Japan, Average Price ($), Historic, 2000-2007

Figure 62: Needle Free Injections, Japan, Average Price ($), Forecast, 2007-2012

Figure 63: Needle Free Injections, Japan, Distribution Share (%), 2006

Figure 64: 3M Company, Value Chain Analysis

Figure 65: Baxter International Inc., Value Chain Analysis

Figure 66: Medical Device Classification in Japan, 2007

Figure 67: Approval Process for Controlled Medical Devices in Japan, 2007

Figure 68: Approval Process for Highly Controlled Medical Devices in Japan, 2007

Figure 69: Health Insurance Reimbursement Process in Japan, 2007

Figure 70: Distribution Structure for Medical Equipment in Japan, 2007

Figure 71: Global Markets Direct Methodology

Abstract

• The report provides drug delivery devices information broken down into detailed categories and segments in Japan.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

• Gain a strong understanding of the drug delivery devices market in Japan.
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.